CytoGenix Inc. and The University of Texas M. D. Anderson Cancer Center Form Collaboration for Melanoma Gene Target Validation.Business Editors/Health & Medical Writers HOUSTON--(BUSINESS WIRE)--Nov. 26, 2002 CytoGenix Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYGX) announced today it has formed a scientific collaboration with Dr. Madeleine Duvic, Professor of Internal Medicine and Dermatology, Division of Internal Medicine and Deputy Chair of Dermatology, The University of Texas M. D. Anderson Cancer Center in Houston, to investigate, test and evaluate a gene believed to be related to melanoma. Building on Dr. Duvic's team's research CytoGenix' scientific team will be using the company's proprietary ssDNA Expression System to construct and deliver target-specific gene knockout sequences to melanoma cancer cells. This work could form the basis for further research into better treatments for this difficult-to-treat disease. The American Cancer Society American Cancer Society, n.pr established in 1913, this national volunteer-based health organization is committed to the elimination of cancer through prevention and treatment and to diminishing cancer suffering through advocacy, scholarship, research, estimates that about 53,600 new melanomas will be diagnosed in the United States during 2002 and 7,400 people are expected to die. Dr. Malcolm Skolnick, CytoGenix' President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , goes on to say, "We are very pleased to be working with Dr. Duvic and with M. D. Anderson, the best cancer hospital in the country. Our ssDNA technology is being used quite effectively by cancer researchers in other institutions to knock out to force out by a blow or by blows; as, to knock out the brains s>. See also: Knock genes related to prostate and to breast cancer. Melanoma is especially lethal because of its propensity to rapidly metastasize me·tas·ta·size v. To be transmitted or transferred by or as if by metastasis. Metastasize Spread of cells from the original site of the cancer to other parts of the body where secondary tumors are formed. , and any possible treatment would certainly save many lives." Dr. Duvic is Associate Medical Director of the Melanoma and Skin Center at M.D. Anderson Cancer Center. She is board certified board certified, adj the status of a dental specialist such as an orthodontist who has become a board diplomate by successfully completing the certification program of the recognized certification board in that area of practice. in internal medicine and dermatology and her research interests include molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller and the pathogenesis of CTCL CTCL Cutaneous T Cell Lymphoma , sezary syndrome and skin cancers. Dr. Duvic received her M.D. from Duke University Medical School. CytoGenix Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. CytoGenix currently has one issued US patent and 36 international or US pending patent applications claiming methods and materials in connection with this platform technology. SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the Web site at www.cytogenix.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion